Iteos Home

Investor FAQs

Home / Investors / Investor FAQs

Investor FAQs

Investor FAQs

Show All
Where is iTeos' corporate headquarters?

They are located at 321 Arsenal St. Bldg 301, Suite 301, Watertown, MA 02472, United States.

When did iTeos go public?

The Company completed its IPO in July 2020.

On what exchange are iTeos’ stock traded and what is the ticker?

iTeos is traded on the NASDAQ Global Market under the ticker ITOS.

Who is iTeos's transfer agent?

Computershare
web.queries@computershare.com
1-800-736-3001, option 1 (U.S.)
1-781-575-3100, option 1 (non-U.S.)

Whom do I contact with questions about my stock?

Should you have questions about your shares, please contact our transfer agent, listed above. For all other investor inquiries, please contact IR@iteostherapeutics.com

Does iTeos have a direct stock purchase plan?

The Company does not currently have a direct stock purchase plan. The Company’s common stock can be purchased by contacting a securities broker of your choice.

Who is iTeos' legal counsel and independent auditor?

Goodwin Procter LLP and DELOITTE

Where can I get the latest corporate news releases and financial reports?

Corporate news can be found in News & Events section of our Investors webpage. Quarterly and annual reports, as well as other SEC filings, can be found in the Financials section of our Investors webpage or directly from the SEC at www.sec.gov.

How can I view documents iTeos has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?

The Company’s annual report on Form 10K can be found in the Financials section of our Investors webpage or directly from the SEC at www.sec.gov.

Whom should I contact regarding investor requests or inquiries?

Please contact IR@iteostherapeutics.com

What analysts cover iTeos?

Our current analyst coverage can be found in the Stock Information section of our Investors webpage.

How can obtain a copy of your annual report and proxy?

The Company’s annual report on Form 10K can be found in the Financials section of our Investors webpage or directly from the SEC at www.sec.gov.

When and where will iTeos’ hold its next annual meeting?

The date and location of the next annual meeting will be communicated prior to the meeting date.

For investors

Discover more about iTeos Therapeutics, our science, and our high potential for investment.

Two scientists in their workstation

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.